On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

BCKDHB

branched chain keto acid dehydrogenase E1 subunit beta

The BCKDHB gene provides instructions for a component of an enzyme complex essential for breaking down specific amino acids, with variants linked to Maple Syrup Urine Disease. The BCKDHB gene is crucial for normal amino acid metabolism, encoding the beta subunit of the branched-chain alpha-keto acid dehydrogenase (BCKD) enzyme complex.

Chromosome 6q14.1 Autosomal recessive HGNC:987 Tier C
BCKDHB 6q14.1 p arm q arm 6

BCKDHB is located on the long (q) arm of chromosome 6, at band 6q14.1. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 6 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The BCKDHB gene, or branched chain keto acid dehydrogenase E1 subunit beta, plays a vital role in human metabolism. It provides the genetic blueprint for a crucial part of the branched-chain alpha-keto acid dehydrogenase (BCKD) enzyme complex. This enzyme complex is responsible for breaking down certain amino acids, which are the building blocks of proteins, that are obtained through diet.

Disruptions to the BCKDHB gene's function can impair this metabolic pathway, leading to the accumulation of substances that can be harmful to the body. This gene is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of a pathogenic variant (one from each parent) to typically develop an associated condition.

What the gene does

The BCKDHB gene produces the beta subunit of the E1 component within the branched-chain alpha-keto acid dehydrogenase (BCKD) enzyme complex. This complex is a multi-enzyme system located in the mitochondria, the energy-producing organelles within cells. The E1 component is formed when two beta subunits, encoded by BCKDHB, combine with two alpha subunits, which are produced from the BCKDHA gene.

The primary function of the BCKD enzyme complex is to catalyse a critical step in the breakdown of three essential branched-chain amino acids: leucine, isoleucine, and valine. These amino acids are consumed as part of a typical diet, found abundantly in protein-rich foods such as meat, milk, and eggs. The metabolic process facilitated by the BCKD complex converts these amino acids into molecules that the body can use for energy production. Efficient functioning of this enzyme is therefore fundamental for proper cellular energy metabolism.

Video: Genetics 101

Chromosome location

The BCKDHB gene is situated on chromosome 6, specifically at position 6q14.1. This precise location on the long arm (q) of chromosome 6 helps define its genomic context within the human genome.

Protein structure

The BCKDHB gene encodes a protein that is 392 amino acids in length and forms the beta subunit of the branched-chain alpha-keto acid dehydrogenase (BCKD) enzyme complex. Domain architecture has not been experimentally characterised in detail for this protein.

Key variants

Genetic variations within the BCKDHB gene can affect the structure and function of the encoded protein, leading to impaired metabolic activity. Over 90 different pathogenic variants have been identified in individuals with associated conditions. These variants typically result in a significant reduction or complete loss of function of the BCKD enzyme complex.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for BCKDHB.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.1007dup
Duplication
p.Phe337fs Pathogenic/Likely pathogenic ★★☆☆ Maple syrup urine disease
c.1095_1096del
Microsatellite
p.Pro366fs Pathogenic/Likely pathogenic ★★☆☆ Maple syrup urine disease
c.187_196+19del
Deletion
- Pathogenic/Likely pathogenic ★★☆☆ Maple syrup urine disease type 1B
c.199C>T
single nucleotide variant
p.Gln67Ter Pathogenic/Likely pathogenic ★★☆☆ Maple syrup urine disease type 1B
c.274+1G>T
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ Maple syrup urine disease type 1A
c.275-1G>A
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ Maple syrup urine disease type 1B
c.360dup
Duplication
p.Asn121Ter Pathogenic/Likely pathogenic ★★☆☆ Maple syrup urine disease type 1B
c.532G>T
single nucleotide variant
p.Gly178Ter Pathogenic/Likely pathogenic ★★☆☆ Maple syrup urine disease type 1A
c.550del
Deletion
p.Ser184fs Pathogenic ★★☆☆ Maple syrup urine disease
c.580C>T
single nucleotide variant
p.Leu194Phe Pathogenic/Likely pathogenic ★★☆☆ Maple syrup urine disease

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Pathogenic variants in the BCKDHB gene are primarily associated with Maple Syrup Urine Disease. This condition is an inherited metabolic disorder characterised by the body's inability to properly break down branched-chain amino acids. The build-up of these amino acids and their byproducts can be toxic, particularly to the brain. Affected individuals often exhibit symptoms such as poor feeding, vomiting, and lethargy, and in its severe form, the disease is apparent shortly after birth.

Inheritance pattern

Conditions caused by pathogenic BCKDHB variants typically follow autosomal recessive inheritance.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Carrier frequency by population How common is heterozygous BCKDHB carrier status across ancestry groups?

UK clinical status

The BCKDHB gene is recognised within the NHS Genomic Medicine Service due to its clinical significance. It is listed as 'green' in several NHS PanelApp panels, including those for DDG2P, Early onset or syndromic epilepsy, Hereditary neuropathy, Hereditary neuropathy or pain disorder (R78), Hyperammonaemia, Intellectual disability, Likely inborn error of metabolism (R98), and Undiagnosed metabolic disorders. This indicates that there is strong evidence for a gene-disease association and that variants in BCKDHB are considered in clinical genetic testing for these conditions.

Frequently asked questions

What is the function of the BCKDHB gene?

The BCKDHB gene provides instructions for making a part of the branched-chain alpha-keto acid dehydrogenase (BCKD) enzyme complex. This enzyme is crucial for breaking down the amino acids leucine, isoleucine, and valine, which are obtained from the diet.

What condition is associated with BCKDHB gene variants?

Pathogenic variants in the BCKDHB gene are primarily associated with Maple Syrup Urine Disease. This inherited metabolic disorder results from the body's inability to properly process certain amino acids, leading to their toxic accumulation.

How is Maple Syrup Urine Disease inherited?

Maple Syrup Urine Disease is inherited in an autosomal recessive pattern. This means an individual must inherit two copies of a pathogenic variant, one from each parent, to develop the condition. Individuals with only one pathogenic variant are typically carriers and do not show symptoms.

References

  1. Quental S, Macedo-Ribeiro S, Matos R. Molecular and structural analyses of maple syrup urine disease and identification of a founder mutation in a Portuguese Gypsy community. Molecular genetics and metabolism. 2008. PMID: 18378174
  2. Flaschker N, Feyen O, Fend S. Description of the mutations in 15 subjects with variant forms of maple syrup urine disease. Journal of inherited metabolic disease. 2007. PMID: 17922217
  3. Rodríguez-Pombo P, Navarrete R, Merinero B. Mutational spectrum of maple syrup urine disease in Spain. Human mutation. 2006. PMID: 16786533
  4. Henneke M, Flaschker N, Helbling C. Identification of twelve novel mutations in patients with classic and variant forms of maple syrup urine disease. Human mutation. 2003. PMID: 14517957
  5. Nellis MM, Danner DJ. Gene preference in maple syrup urine disease. American journal of human genetics. 2001. PMID: 11112664
  6. Edelmann L, Wasserstein MP, Kornreich R. Maple syrup urine disease: identification and carrier-frequency determination of a novel founder mutation in the Ashkenazi Jewish population. American journal of human genetics. 2001. PMID: 11509994
  7. Adam MP, Bick S, Mirzaa GM. Maple Syrup Urine Disease. 1993. PMID: 20301495
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 11 October 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .